Copyright
©The Author(s) 2021.
World J Gastroenterol. Dec 21, 2021; 27(47): 8166-8181
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8166
Published online Dec 21, 2021. doi: 10.3748/wjg.v27.i47.8166
Table 4 Site of first progression in all cases of progression
| All procedures (n = 169) | TARE_alone (n = 63) | TARE_sorafenib (n = 81) | TARE_no_sorafenib (n = 25) | |
| No progression | 58 (34.3) | 27 (42.9) | 24 (29.6) | 7 (28) |
| Progression | 111 (65.7) | 36 (57.1) | 57 (70.4) | 18 (72) |
| Intrahepatic only | 67 (39.6) | 28 (44.5) | 31 (38.4) | 8 (32) |
| Treated area only | 36 (21.3) | 16 (25.4) | 17 (21) | 3 (12) |
| Untreated area only | 20 (11.8) | 10 (15.9) | 6 (7.4) | 4 (16) |
| Both treated and untreated areas | 11 (6.5) | 2 (3.2) | 8 (9.9) | 1 (4) |
| Extrahepatic only | 17 (10.1) | 3 (4.8) | 13 (16) | 1 (4) |
| Intra- and extrahepatic | 27 (16) | 5 (7.9) | 13 (16) | 9 (36) |
- Citation: Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol 2021; 27(47): 8166-8181
- URL: https://www.wjgnet.com/1007-9327/full/v27/i47/8166.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i47.8166